ADVERTISEMENT
Lupin to sustain 'excellent' track record: Citi
If you missed our coverage, here are the top 10 stories of the day.
16 Jul 2012, 02:01 PM IST 
Anand Shimpi (Image courtesy: theverge.com)
Citigroup raises its target price of drug maker Lupin to Rs 640 from Rs 570, while maintaining its "buy" rating, after meeting with management. Lupin shares last up 3.1 per cent at Rs 572.05.
